Xin Zhang

Xin Zhang

Auto-generated profile, based on publicly available information

Xin Zhang

Cancer Research Institute School of Basic Medical Sciences State Key Laboratory of Multi‐organ Injury Prevention and Treatment Guangdong Province Key Laboratory of Immune Regulation and Immunotherapy Southern Medical University Guangzhou 510515 China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2023 in Genome Biology
Verified
Journal Article
Open access
PDF file
XZXin Zhang
Xin Zhang
XWXinlong Wang
Xinlong Wang
JLJie Lv
Jie Lv
HHHongxin Huang
Hongxin Huang
JWJiahong Wang
Jiahong Wang
ZRZhili Rong
Zhili Rong
Background: The CRISPR/Cas12a and CRISPR/Cas13d systems are widely used for fundamental research and hold great potential for future clinical applications. However, the short half-life of guide RNAs (gRNAs), particularly free gRNAs without Cas nuclease binding, limits their editing efficiency and durability. Results: Here, we engineer circular free gRNAs (cgRNAs) to increase their stability, and thus availability for Cas12a and Cas13d processing and loading, to boost editing. cgRNAs increases the efficiency of Cas12a-based transcription activators and genomic DNA cleavage by approximately 2.1- to 40.2-fold for single gene editing and 1.7- to 2.1-fold for multiplexed gene editing than their linear counterparts, without compromising specificity, across multiple sites and cell lines. Similarly, the RNA interference efficiency of Cas13d is increased by around 1.8-fold. In in vivo mouse liver, cgRNAs are more potent in activating gene expression and cleaving genomic DNA. Conclusions: CgRNAs enable more efficient programmable DNA and RNA editing for Cas12a and Cas13d with broad applicability for fundamental research and gene therapy.

25 April 2022 in BMC Biology
Verified
Journal Article
Open access
PDF file
HHHongxin Huang
Hongxin Huang
GHGuanjie Huang
Guanjie Huang
ZTZhihong Tan
Zhihong Tan
YHYongfei Hu
Yongfei Hu
LSLin Shan
Lin Shan
ZRZhili Rong
Zhili Rong
Background: The CRISPR-Cas12a (formerly Cpf1) system is a versatile gene-editing tool with properties distinct from the broadly used Cas9 system. Features such as recognition of T-rich protospacer-adjacent motif (PAM) and generation of sticky breaks, as well as amenability for multiplex editing in a single crRNA and lower off-target nuclease activity, broaden the targeting scope of available tools and enable more accurate genome editing. However, the widespread use of the nuclease for gene editing, especially in clinical applications, is hindered by insufficient activity and specificity despite previous efforts to improve the system. Currently reported Cas12a variants achieve high activity with a compromise of specificity. Here, we used structure-guided protein engineering to improve both editing efficiency and targeting accuracy of Acidaminococcus sp. Cas12a (AsCas12a) and Lachnospiraceae bacterium Cas12a (LbCas12a). Results: We created new AsCas12a variant termed “AsCas12a-Plus” with increased activity (1.5~2.0-fold improvement) and specificity (reducing off-targets from 29 to 23 and specificity index increased from 92% to 94% with 33 sgRNAs), and this property was retained in multiplex editing and transcriptional activation. When used to disrupt the oncogenic BRAFV600E mutant, AsCas12a-Plus showed less off-target activity while maintaining comparable editing efficiency and BRAFV600E cancer cell killing. By introducing the corresponding substitutions into LbCas12a, we also generated LbCas12a-Plus (activity improved ~1.1-fold and off-targets decreased from 20 to 12 while specificity index increased from 78% to 89% with 15 sgRNAs), suggesting this strategy may be generally applicable across Cas12a orthologs. We compared Cas12a-Plus, other variants described in this study, and the reported enCas12a-HF, enCas12a, and Cas12a-ultra, and found that Cas12a-Plus outperformed other variants with a good balance for enhanced activity and improved specificity. Conclusions: Our discoveries provide alternative AsCas12a and LbCas12a variants with high specificity and activity, which expand the gene-editing toolbox and can be more suitable for clinical applications.

24 April 2023 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
SMShufeng Ma
Shufeng Ma
KLKaitong Liao
Kaitong Liao
MLMengrao Li
Mengrao Li
XWXinlong Wang
Xinlong Wang
JLJie Lv
Jie Lv
ZRZhili Rong
Zhili Rong
Liquid–liquid phase separation (LLPS) plays a critical role in regulating gene transcription via the formation of transcriptional condensates. However, LLPS has not been reported to be engineered as a tool to activate endogenous gene expression in mammalian cells or in vivo. Here, we developed a droplet-forming CRISPR (clustered regularly interspaced short palindromic repeats) gene activation system (DropCRISPRa) to activate transcription with high efficiency via combining the CRISPR-SunTag system with FETIDR–AD fusion proteins, which contain an N-terminal intrinsically disordered region (IDR) of a FET protein (FUS or TAF15) and a transcription activation domain (AD, VP64/P65/VPR). In this system, the FETIDR–AD fusion protein formed phase separation condensates at the target sites, which could recruit endogenous BRD4 and RNA polymerase II with an S2 phosphorylated C-terminal domain (CTD) to enhance transcription elongation. IDR-FUS9Y>S and IDR-FUSG156E, two mutants with deficient and aberrant phase separation respectively, confirmed that appropriate phase separation was required for efficient gene activation. Further, the DropCRISPRa system was compatible with a broad set of CRISPR-associated (Cas) proteins and ADs, including dLbCas12a, dAsCas12a, dSpCas9 and the miniature dUnCas12f1, and VP64, P65 and VPR. Finally, the DropCRISPRa system could activate target genes in mice. Therefore, this study provides a robust tool to activate gene expression for foundational research and potential therapeutics.

27 January 2021 in Protein & Cell
Verified
Journal Article
Open access
PDF file
JLJun Liu
Jun Liu
JCJunchen Chen
Junchen Chen
YZYadan Zhong
Yadan Zhong
XYXiaoling Yu
Xiaoling Yu
PLPing Lu
Ping Lu
ZRZhili Rong
Zhili Rong

18 July 2025 in Advanced Science
Verified
Journal Article
Open access
THTao Huang
Tao Huang
SCShijun Chen
Shijun Chen
KDKe Ding
Ke Ding
LYLiyan Yuan
Liyan Yuan
WLWeiqi Lv
Weiqi Lv
ZRZhili Rong
Zhili Rong
Impaired N6‐methyladenosine (m 6 A) modification has been implicated in regulating various inflammatory diseases, but its role in psoriasis remains unclear. Here, m 6 A modification and its methyltransferase METTL3 are revealed to be upregulated in psoriatic macrophages, while the demethylase ALKBH5 is downregulated. Conditional knockout of Mettl3 in macrophages alleviated psoriasis‐like symptoms in mice, whereas knockout of Alkbh5 exacerbated them. Both in vivo and in vitro, Mettl3 deficiency inhibited IMQ‐induced M1 macrophage polarization, while Alkbh5 deficiency promoted M1 polarization. The regulation of macrophage polarization by m 6 A is likely mediated by targeting Slc15a3 . SLC15A3 enhances the recruitment of TASL, a recently identified endolysosomal IRF5 adaptor, which functions similarly to the IRF3 adaptors STING and MAVS at the endoplasmic reticulum (ER) and mitochondria, respectively, to augment IRF5 signaling via SLC15A4. The findings underscore the critical role of m 6 A RNA modification in psoriasis pathogenesis and unveil a novel regulatory mechanism of TASL‐IRF5 signaling through m 6 A modification, suggesting potential new therapeutic targets for psoriasis treatment.